Table 2.
Pacemaker parameters after 24-month follow-up in olmesartan and control groups in this study
| Parameters | Olmesartan group (n = 57) | Control group (n = 59) | Statistical values | P |
|---|---|---|---|---|
| AP (%) | 12.6 ± 7.3 | 13.9 ± 5.2 | −1.10* | 0.18 |
| VP (%) | 71.6 ± 22.0 | 72.2 ± 18.7 | −0.09* | 0.89 |
| Patients occurred new-onset AF | 10 (17.5) | 24 (40.7) | 5.19† | 0.04 |
| Days to the first occurrence of AHREs (days) | 293.8 ± 197.5 | 286.7 ± 191.7 | −0.14* | 0.89 |
| Cumulative numbers of AHREs (episodes/patient) | 22.8 ± 19.2 | 28.4 ± 18.4 | 0.13* | 0.42 |
| Duration of AHRE episodes (h/day) | 1.93 ± 0.75 | 3.29 ± 1.45 | 2.78* | 0.04 |
| AF burden (%) | 8.02 ± 3.10 | 13.66 ± 6.14 | – | 0.04 |
Data are shown as mean ± SD or n (%). *t value; †χ2 value. AF: Atrial fibrillation; AP: Atrial pacing; VP: Ventricular pacing; AHREs: Atrial high rate episodes; SD: Standard deviation; –: Not applicable.